- Active, not recruiting
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
Updated: Sep 25, 2022
EMN
European Myeloma Network
NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (CCD)
The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).
Sponsor
Collaborator
Fondazione EMN Italy Onlus
ClinicalTrials.gov Identifier: NCT01346787
Official Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
IST-CAR-506
First Posted : May 3, 2011
Click here for details on ClinicalTrials.gov
Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
Haematologica;2021
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Haematologica;2020
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Haematologica;2019
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
Once-weekly 70 mg/m2 carfilzomib as induction and maintenance therapy for newly diagnosed multiple myeloma patients was as safe and effective as twice-weekly 36 mg/m2 carfilzomib and provided a more convenient schedule. The trials are registered at clinicaltrials.gov
Blood;2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
Blood;2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
In summary, results showed high complete response rates and a good safety profile. This trial was registered at clinicaltrials.gov
Locations
Europe
Italy
Netherlands